Long-Term Consequences of Chronic Active EBV Infection
Chronic active EBV infection (CAEBV) carries severe long-term consequences including progression to life-threatening hemophagocytic lymphohistiocytosis (HLH), multi-organ failure, malignant transformation to T-cell or NK-cell lymphomas/leukemias, and death, with the majority of patients having a poor prognosis without hematopoietic cell transplantation. 1
Mortality and Disease Progression
The long-term outlook for CAEBV is grave. The majority of patients with severe chronic active EBV infection have a poor prognosis, with the disease representing a neoplastic smoldering process highly associated with certain EBV-associated T-cell lymphomas 1. The clinical course is heterogeneous—some patients remain stable for years with an indolent course, while others experience aggressive progression with fatal outcomes 2.
Key Prognostic Factors
Poor outcomes are specifically associated with:
- Late onset of disease
- Thrombocytopenia at presentation
- EBV infection of T cells (particularly CD4+ T-cells, which show significantly lower survival rates) 1, 3
The 3-year overall survival in one recent cohort was 88%, but this included patients who underwent curative hematopoietic cell transplantation 3. CD4+ T-cell dominant CAEBV requires prompt rather than elective transplantation to prevent progression and transformation 3.
Malignant Transformation
A critical long-term consequence is malignant transformation to lymphoma or leukemia. Among patients who remained untreated for over 10 years without transplantation, cases of CD4+ T-cell or NK-cell CAEBV transformed to lymphoma or leukemia 3. The disease is characterized by clonal expansion of EBV-infected T cells and/or NK cells with multi-organ infiltration 4.
Life-Threatening Complications
Hemophagocytic Lymphohistiocytosis (HLH)
CAEBV is frequently complicated by EBV-associated hemophagocytic lymphohistiocytosis, a life-threatening hyperinflammatory syndrome 1, 5. This represents one of the most acute and severe complications requiring immediate intervention.
Cardiovascular Complications
Rare but devastating cardiovascular complications can develop, including:
- Giant coronary artery aneurysms and thrombosis
- Valsalva sinus aneurysms
- Ascending aorta dilation
These complications can occur years after initial infection and carry a fatal prognosis 5. One documented case showed these cardiovascular manifestations developing seven years after disease onset, ultimately resulting in death 5.
Multi-Organ Involvement
The disease causes systemic inflammation with multi-organ infiltration by infected cells 4. Documented complications include:
- Hematological disorders
- Digestive tract involvement
- Neurological complications
- Pulmonary disease
- Ocular manifestations
- Dermal lesions (including hypersensitivity to mosquito bites)
- Cardiovascular disorders (including aneurysms and valvular disease) 1
Disease Characteristics
CAEBV is characterized by:
- Persistent or recurrent infectious mononucleosis-like symptoms (fever, lymphadenopathy, hepatosplenomegaly)
- Markedly elevated EBV DNA load in peripheral blood (generally >10^2.5 copies/mg DNA in peripheral blood mononuclear cells) 1, 4
- Systemic inflammation
- Unusual infection of T cells and/or NK cells rather than the typical B-cell infection 1, 4
Critical Clinical Pitfall
The most important pitfall is delayed diagnosis and treatment. CAEBV can be misdiagnosed as other conditions (such as incomplete Kawasaki disease in the documented case with cardiovascular complications) 5. Regular long-term follow-up is essential, as complications can emerge years after initial infection. Clinicians must maintain high suspicion for CAEBV in patients with persistent EBV-related symptoms and monitor for progression to HLH, malignancy, or organ-specific complications 5.
Treatment Implications
Without curative hematopoietic cell transplantation, the long-term prognosis remains poor 3. The indication and timing of transplantation should be guided by EBV-infected lymphocyte profiling, with CD4+ T-cell dominant disease requiring prompt transplantation rather than watchful waiting 3. Even among patients achieving prolonged progression-free survival without transplantation (median 11 years in one cohort), the risk of eventual malignant transformation persists 3.